摘要
目的:观察重组腺病毒AdCD/5-FC体外对肿瘤细胞的抑制作用。方法:以pBluescriptCD为模板,经PCR扩增CD基因片段,然后与酶切后的腺病毒AdLacZ DNA右臂共转染293细胞,通过同源性重组构建重组腺病毒AdCD。在体外用AdCD/5-FT系统分别对乳腺癌、肺癌和宫颈癌进行细胞生长抑制实验,同时观察了旁杀伤作用。结果:经AdCD/5-FC系统处理的瘤细胞明显受抑制,抑制率随AdCD/5-FC浓度及作用时间的增加而升高。同时,观察到AdCD有明显的旁杀伤作用,当其比例为70％以上时,细胞杀伤率接近100％。结论:AdCD/5-FC治疗系统在体外对乳腺癌、肺癌及宫颈癌有极强抑瘤作用,这一结果为临床肿瘤的基因治疗奠定了理论及应用基础。
Objective: To study the antitumor effect of recombinant adenovirus AdCD/5-FC in vitro. Methods: AdCD was constructed by cotransfection of 293 cells by shuttle plasmid pAdEICMV and cutted AdLacZ DNA. Then it was used to inhibit the cell growth of mammary cancer, cancer of lung and cervical carcinoma in vitro with prorug 5-FC. At the same time, its by stander effect was observed. Results: AdCD/5-FC therapeutic system had an extremely strong antitumor effect on mammary cancer, cancer of lung and cervical carcinoma in vitro. It also had an obvious by stander effect. Conclusion: The Ad-CD/5-FC therapeutic system may be regarded as a strategy of gene therapy for local control of growth of tumor cells susceptible to 5-FC.
出处
《天津医药》
CAS
北大核心
2002年第5期291-294,共4页
Tianjin Medical Journal
